Clinical Trial Update: ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ModraDoc006/r to Docetaxel IV in metastatic castration-resistant prostate cancer has completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ModraDoc006/r

Snippet

Sponsor: Modra Pharmaceuticals | Conditions: Prostate Cancer Metastatic, Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-04-17